Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval from the U.S Food and Drug Administration (USFDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial. Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension. The approval further adds to Biocon’s portfolio of complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
